newsfilter
← Latest News
GlobeNewswire·

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper